Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,289 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT06799026RecruitingPhase 1
Vaccine plus elranatamab for advanced multiple myeloma
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Boston, MassachusettsAges 18 years+ - NCT06348108RecruitingPhase 1
Talquetamab with iberdomide for relapsed or refractory multiple myeloma
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT04603872RecruitingEarly Phase 1
CAR-T plus dasatinib for hard-to-treat B-cell cancers
This early study tests a cancer-fighting treatment that uses CAR-T cells together with dasatinib for people whose B-cell cancers have come back or did not respond. It aims to improve control of the cancer in cases that are often resistant to standard treatment.
Hangzhou, ZhejiangAges 18–70 - NCT07772024RecruitingPhase 3
Testing a new drug combo for relapsed or refractory multiple myeloma
This study tests a new drug combination, inobrodib plus pomalidomide and dexamethasone, in people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this combination works better than the standard available treatments.
Miami, FloridaAges 18 years+ - NCT07096778RecruitingPhase 2
Study of Inobrodib, Pomalidomide, and Dexamethasone for Multiple Myeloma
This trial tests a new combination of three drugs—inobrodib, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug adds benefit for patients who have tried other therapies.
Phoenix, ArizonaAges 18 years+ - NCT04657861RecruitingEarly Phase 1
BCMA/TACI CAR-T for relapsed or refractory multiple myeloma
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06433947RecruitingPhase 1
Testing an experimental drug OPN-6602 for advanced multiple myeloma
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Gilbert, ArizonaAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07479979RecruitingPhase 1/Phase 2
Study of selinexor with carfilzomib, isatuximab and dexamethasone for relapsed/refractory multiple myeloma
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Madison, WisconsinAges 18 years+ - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT06627751RecruitingPhase 2
Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Buffalo, New YorkAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT06375044RecruitingPhase 1
Study of SIM0500 for relapsed or refractory multiple myeloma
This trial tests a new medication, SIM0500, for people whose multiple myeloma has returned or stopped responding to other treatments. It aims to see if the drug is safe and effective for those who have tried all standard options.
Phoenix, ArizonaAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Birmingham, AlabamaAges 18 years+ - NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
Los Alamitos, CaliforniaAges 18 years+ - NCT05565807RecruitingPhase 1/Phase 2
Study drug for difficult myeloma after prior treatments
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT05913804RecruitingPhase 1
Study of YTS104 cell therapy for hard-to-treat myeloma
This Phase 1 study tests an injected cell therapy (YTS104) for people with multiple myeloma that has come back or did not respond after several prior treatments. The goal is to see whether the treatment is safe and may help control the disease.
TianjinAges 18–75
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Relapsed or Refractory Multiple Myeloma trials by city
Studies with a site in or near these metro areas.
Relapsed or Refractory Multiple Myeloma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,289 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.